CD44细胞
癌症研究
车站3
彭布罗利珠单抗
生物
医学
癌症
背景(考古学)
癌细胞
异位表达
细胞
STAT蛋白
转录因子
癌症干细胞
重编程
癌变
靶向治疗
组织微阵列
免疫检查点
小RNA
作者
Keita Goto,Kiyohiro Ando,Noriko Motoi,Toshihiko Iizuka,Hirotaka Fuchizawa,Yuki Nakamura,Yuta Sano,Shotaro Matsuoka,Hisanori Takenobu,Masayuki Haruta,Ritsuko Onuki,Yoh Matsuoka,Takehiko Kamijo,Yukio Kageyama
出处
期刊:Anticancer Research
[International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts]
日期:2026-04-28
卷期号:46 (5): 2445-2453
被引量:1
标识
DOI:10.21873/anticanres.18129
摘要
BACKGROUND/AIM: Cancer cell plasticity is tightly linked to therapeutic resistance in urothelial carcinoma (UC). Signal transducer and activator of transcription 3 (STAT3) and CD44 play crucial roles in plasticity, but their potential crosstalk in the therapeutic context has not yet been fully elucidated. This study aimed to unveil the shared and distinct roles of STAT3 and CD44 and obtain a better understanding of targeted therapy in UC. MATERIALS AND METHODS: T24 bladder cancer cells were genetically ablated for STAT3 and CD44 and their plasticity was subsequently assessed. Phosphorylated-STAT3 (pSTAT3) and CD44 expression was determined using tissue microarrays in 16 patients who received pembrolizumab therapy for UC, and the association of their expression levels with patient prognosis was investigated. RESULTS: Ablation of STAT3 or CD44 expression resulted in the dysregulation of vimentin expression and promotion of cell spheroid viability. Patients with imbalanced pSTAT3 and CD44 expression had significantly shorter progression-free survival and overall survival. CONCLUSION: Functional imbalance of STAT3 and CD44 may promote cancer cell plasticity and result in impaired pembrolizumab response in patients with advanced UC.
科研通智能强力驱动
Strongly Powered by AbleSci AI